Edmond DE Rothschild Holding S.A. Takes $254,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Edmond DE Rothschild Holding S.A. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 10,500 shares of the company’s stock, valued at approximately $254,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Crewe Advisors LLC purchased a new position in Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. grew its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $38,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

HIMS opened at $31.16 on Thursday. The stock’s 50 day simple moving average is $39.97 and its 200 day simple moving average is $29.79. The firm has a market cap of $6.92 billion, a price-to-earnings ratio of 70.82 and a beta of 1.37. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HIMS. Citigroup reaffirmed a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. Leerink Partners upped their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Bank of America boosted their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Finally, Piper Sandler lifted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $37.31.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the transaction, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Soleil Boughton sold 3,236 shares of the firm’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the sale, the insider now owns 170,285 shares of the company’s stock, valued at $4,728,814.45. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,064,954 shares of company stock valued at $37,984,259 in the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.